Share on LinkedInShare on LinkedIn

ARTICLE · 20 APRIL 2011

OFT Issues Fining Decision For Gaviscon Abuse

The Office of Fair Trading ('OFT') has fined the consumer goods group Reckitt Benckiser £10.2 million in relation to its Gaviscon anti-heartburn product, for infringing Article 102 of the TFEU and the Chapter II prohibition of the UK Competition Act 1998.

United KingdomAntitrust/Competition Law
SJ Berwin'S EU & Competition Team
SJ Berwin'S EU & Competition Team

The Office of Fair Trading ('OFT') has fined the consumer goods group Reckitt Benckiser £10.2 million in relation to its Gaviscon anti-heartburn product, for infringing Article 102 of the TFEU and the Chapter II prohibition of the UK Competition Act 1998. The fine was the subject of an 'early resolution' agreement under which, in return for a reduced fine, the company admitted its conduct infringed both UK and EU competition law and agreed to co-operate with the OFT. Under this arrangement, the fine was reduced by 15% - from £12 million to £10.2 million.

The fine relates to Reckitt Benckiser's decision to withdraw and de-list National Health Service ('NHS') packs of Gaviscon Original Liquid (the 'Original') from the NHS prescription channel in 2005, this being after the expiration of its patent for the product but before the generic name for the product had been assigned. When an out-of-patent drug has expired it is assigned a generic name. General

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from